APONTIS PHARMA AG (APPH.DE) Stock Fundamental Analysis
FRA:APPH - Deutsche Boerse Ag - DE000A3CMGM5 - Common Stock - Currency: EUR
We assign a fundamental rating of 4 out of 10 to APPH. APPH was compared to 52 industry peers in the Pharmaceuticals industry. APPH has a great financial health rating, but its profitability evaluates not so good. APPH is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year APPH was profitable.
APPH had a negative operating cash flow in the past year.
In multiple years APPH reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: APPH reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.82%, APPH is doing worse than 60.78% of the companies in the same industry.
Looking at the Return On Equity, with a value of 4.03%, APPH is doing worse than 60.78% of the companies in the same industry.
The Return On Invested Capital of APPH (2.95%) is worse than 60.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.82% | ||
| ROE | 4.03% | ||
| ROIC | 2.95% |
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APPH has a worse Profit Margin (1.75%) than 60.78% of its industry peers.
APPH has a Operating Margin of 2.47%. This is in the lower half of the industry: APPH underperforms 64.71% of its industry peers.
In the last couple of years the Operating Margin of APPH has declined.
Looking at the Gross Margin, with a value of 57.57%, APPH is doing worse than 66.67% of the companies in the same industry.
In the last couple of years the Gross Margin of APPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.47% | ||
| PM (TTM) | 1.75% | ||
| GM | 57.57% |
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), APPH is destroying value.
APPH has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, APPH has less shares outstanding
There is no outstanding debt for APPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
APPH has an Altman-Z score of 5.99. This indicates that APPH is financially healthy and has little risk of bankruptcy at the moment.
APPH has a Altman-Z score of 5.99. This is amongst the best in the industry. APPH outperforms 86.27% of its industry peers.
APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.99 |
ROIC/WACC0.42
WACC7.02%
2.3 Liquidity
A Current Ratio of 4.44 indicates that APPH has no problem at all paying its short term obligations.
With an excellent Current ratio value of 4.44, APPH belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
APPH has a Quick Ratio of 3.37. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of APPH (3.37) is better than 94.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.44 | ||
| Quick Ratio | 3.37 |
3. Growth
3.1 Past
APPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 106.67%, which is quite impressive.
APPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.12%.
Measured over the past years, APPH shows a small growth in Revenue. The Revenue has been growing by 3.89% on average per year.
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.67%
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%43.76%
3.2 Future
The Earnings Per Share is expected to grow by 128.83% on average over the next years. This is a very strong growth
Based on estimates for the next years, APPH will show a quite strong growth in Revenue. The Revenue will grow by 15.31% on average per year.
EPS Next Y290.99%
EPS Next 2Y175.34%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue Next Year10.35%
Revenue Next 2Y16.83%
Revenue Next 3Y19.03%
Revenue Next 5Y15.31%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 72.33, the valuation of APPH can be described as expensive.
Based on the Price/Earnings ratio, APPH is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
APPH is valuated expensively when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 24.51 indicates a rather expensive valuation of APPH.
APPH's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. APPH is more expensive than 62.75% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.09, APPH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 72.33 | ||
| Fwd PE | 24.51 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of APPH indicates a slightly more expensive valuation: APPH is more expensive than 62.75% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.15 |
4.3 Compensation for Growth
APPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
APPH's earnings are expected to grow with 128.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y175.34%
EPS Next 3Y128.83%
5. Dividend
5.1 Amount
APPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:APPH (8/8/2025, 7:00:00 PM)
10.85
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.82%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap92.22M
Analysts37.78
Price Target10.2 (-5.99%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25.93%
PT rev (3m)-25.93%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.82%
Revenue NY rev (3m)-4.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 72.33 | ||
| Fwd PE | 24.51 | ||
| P/S | 1.29 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.97 | ||
| P/tB | 6.9 | ||
| EV/EBITDA | 19.15 |
EPS(TTM)0.15
EY1.38%
EPS(NY)0.44
Fwd EY4.08%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS8.43
BVpS3.65
TBVpS1.57
PEG (NY)0.25
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.82% | ||
| ROE | 4.03% | ||
| ROCE | 4.51% | ||
| ROIC | 2.95% | ||
| ROICexc | 4.86% | ||
| ROICexgc | 18.85% | ||
| OM | 2.47% | ||
| PM (TTM) | 1.75% | ||
| GM | 57.57% | ||
| FCFM | N/A |
ROA(3y)-4.49%
ROA(5y)-3.77%
ROE(3y)-9.48%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-34.78%
ROICexcg growth 5YN/A
ROICexc growth 3Y-37.05%
ROICexc growth 5YN/A
OM growth 3Y-32.75%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
F-Score5
Asset Turnover1.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 104.52% | ||
| Cap/Sales | 3.27% | ||
| Interest Coverage | 13.13 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.44 | ||
| Quick Ratio | 3.37 | ||
| Altman-Z | 5.99 |
F-Score5
WACC7.02%
ROIC/WACC0.42
Cap/Depr(3y)153.41%
Cap/Depr(5y)119.86%
Cap/Sales(3y)6.51%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.67%
EPS Next Y290.99%
EPS Next 2Y175.34%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%43.76%
Revenue Next Year10.35%
Revenue Next 2Y16.83%
Revenue Next 3Y19.03%
Revenue Next 5Y15.31%
EBIT growth 1Y113.23%
EBIT growth 3Y-33.96%
EBIT growth 5YN/A
EBIT Next Year419.89%
EBIT Next 3Y131.3%
EBIT Next 5YN/A
FCF growth 1Y66.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.97%
OCF growth 3YN/A
OCF growth 5YN/A